Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 13/20 | 0.62 |
| ▸ | CTSK | P43235 | 1/20 | 0.37 |
| ▸ | GCG | P01275 | 1/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
| ▸ | TDO2 | P48775 | 1/20 | 0.34 |
| ▸ | CPB1 | P15086 | 1/20 | 0.34 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.34 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1711521 | 1.00 | GCK (0.62) | GCKCTSKGCGP2RX7ALDH1A1 | |
| SCHEMBL1711692 | 0.99 | GCK (0.63) | GCKCTSKGCGP2RX7 | |
| SCHEMBL1711694 | 0.99 | GCK (0.63) | GCKCTSKGCGP2RX7 | |
| SCHEMBL3353856 | 0.89 | GCK (0.52) | GCKP2RX7 | |
| SCHEMBL3353852 | 0.89 | GCK (0.52) | GCKP2RX7 | |
| SCHEMBL2224423 | 0.84 | GCK (0.63) | GCKGCGIDO1TDO2CPB1 | |
| SCHEMBL3355117 | 0.84 | GCK (0.63) | GCKGCGIDO1TDO2CPB1 | |
| SCHEMBL2195109 | 0.83 | GCK (0.60) | GCKGCGP2RX7IDO1TDO2 | |
| SCHEMBL1712291 | 0.83 | GCK (0.60) | GCKGCGP2RX7IDO1TDO2 | |
| SCHEMBL2199042 | 0.83 | GCK (0.60) | GCKIDO1TDO2CPB1CPB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130165452-A1 | Substituted Heteroaryls | PFIZER INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-8389552-B2 | (S)-6-(2-(4-(cyclobutylsulfonyl)-1H-imidazol-1-yl)-3-cyclopentylpropanamido)nicotinic acid useful as a glucokinase activator | PFIZER INC. (US) | 2013-03-05 | — | — | US | disclosed |
| US-8329920-B2 | Substituted imidazoles useful for treating type II diabetes | PFIZER INC. (US) | 2012-12-11 | — | — | US | disclosed |
| US-20120225910-A1 | Substituted Heteroaryls | PFIZER INC. (US) | 2012-09-06 | — | — | US | disclosed |
| CN-102216276-A | substituted heteroaryl | PFIZER | 2011-10-12 | — | — | CN | disclosed |
| US-20110230445-A1 | Substituted Heteroaryls | PFIZER INC | 2011-09-22 | — | — | US | disclosed |
| EP-2344458-A1 | HETEROARYLS AMIDE DERIVATIVES AND THEIR USE AS GLUCOKINASE ACTIVATORS | Pfizer Inc. (US) | 2011-07-20 | — | — | EP | disclosed |
| US-7977367-B2 | Substituted imidazole propanamide glucokinase activators | PFIZER INC (US) | 2011-07-12 | — | — | US | disclosed |
| US-20100063063-A1 | Substituted Heteroaryls | PFIZER INC | 2010-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120225910-A1 | Substituted Heteroaryls | GCKR, GCK, GALK1 | GCK 2/4885CTSK 296/4885GCG 235/4885 |
| US-20110230445-A1 | Substituted Heteroaryls | GCKR, GCK, GALK1 | GCK 2/4885CTSK 295/4885GCG 263/4885 |
| US-20100063063-A1 | Substituted Heteroaryls | GCKR, GCK, GALK1 | GCK 2/4885CTSK 295/4885GCG 263/4885 |
| US-20130165452-A1 | Substituted Heteroaryls | GCKR, GCK, GALK1 | GCK 2/4885CTSK 295/4885GCG 263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.